Andromeda Biotech has completed recruitment for the Phase III clinical trial.
Andromeda Biotech Ltd. has completed recruitment for the Phase III clinical trial of its treatment for type 1 (juvenile) diabetes, Diapep-277. 40 patients will be included in the trial at three medical centers to collect data on the long-term safety and efficacy of the drug on patients who have completed two years of treatment.
Andromeda expects to obtain results after 24 months of treatment from the recruitment date of the patients.
Clal Biotechnology Industries Ltd. (TASE: CBI) owns 84% of Andromeda, and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) owns the rest.
Published by Globes [online], Israel business news - www.globes-online.com - on February 20, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011